Navigation Links
CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Date:10/30/2008

in tissue processing revenues was due primarily to increased demand for the Company's cardiac and vascular processed tissues, the introduction of the CryoValve(R) SG pulmonary human heart valve and, to a lesser extent, price increases, partially offset by a decline in orthopaedic tissue processing revenues.

Combined cardiac and vascular tissue processing revenues in the third quarter of 2008 increased 31 percent to $14.2 million compared to $10.8 million in the third quarter of 2007. Combined cardiac and vascular tissue processing revenues in the first nine months of 2008 increased 26 percent to $40.7 million compared to $32.4 million in the first nine months of 2007.

Revenues from the distribution of CryoValve SG pulmonary human heart valves were $1.7 million and $3.4 million, respectively, for the three and nine months ended September 30, 2008.

Orthopaedic tissue processing revenues in the third quarter of 2008 decreased to $38,000 from $566,000 in the third quarter of 2007. Orthopaedic tissue processing revenues in the first nine months of 2008 decreased to $662,000 from $3.7 million in the first nine months of 2007. These revenue declines were anticipated as the Company discontinued procuring and processing orthopaedic tissue in January of 2007 pursuant to the exchange and service agreement signed with a third party in December 2006.

BioGlue(R) Surgical Adhesive revenues were $11.6 million for the third quarter of 2008 compared to $10.3 million in the third quarter of 2007, an increase of 13 percent. BioGlue revenues were $36.5 million for the first nine months of 2008 compared to $32.4 million for the first nine months of 2007, an increase of 13 percent.

U.S. BioGlue revenues were $8.1 million and $7.4 million in the third quarter of 2008 and 2007, respectively. U.S. BioGlue revenues were $25.8 million and $23.4 million in the first nine months of 2008 and 2007, respectively. International BioGlue revenues were $3.5 million an
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
2. Concuity Announces the Launch of Its New Fully Accessible Website - Concuity.Com
3. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
4. Life on Mars pregnancy test successfully launched
5. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope
8. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series
11. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... measurement and control provider, is pleased to release ... family of mass flow products designed to be ... on a standard 1.125-inch wide platform with a ... B-Series provides a compact flow measurement and control ...
... announced it has been awarded a 5-year, $17.8 million ... (USAID) to lead a team of organizations in improving ... a member of the North American Free Trade Agreement ... States. USAID programs support Mexican efforts to strengthen ...
... Department in State of Qatar to Introduce State-of-the-Art ... One of the leading cancer centers in the ... from Varian Medical Systems (NYSE: VAR ... precise treatments. Al Amal Hospital in Doha, Qatar, ...
Cached Biology Technology:Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 2Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 3USAID Selects Abt Associates to Lead Team in Strengthening Mexico Private Sector Competitiveness 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3
(Date:4/17/2014)... detection cartridge developed at Sandia National Laboratories and recently ... faster and cheaper. , Bacillus anthracis , ... soils all over the world and can cause serious, ... The bacteria can survive in harsh conditions for decades. ... occur through skin contact, inhalation of spores or eating ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... Kansas State,University, with collaboration from Epitopix LLC, have ... E. coli O157 in beef cattle. ... the post-harvest food safety,aspect, whether it,s E. ... College of Veterinary Medicine. Thomson is the Jones,Professor ...
... German . The Aarhus University ... between the many conference participants and according to ... Kyoto was very successful in doing so: "I am ... will undoubtedly contribute significantly to the future climate debate ...
Cached Biology News:Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Seven recommendations from Aarhus to COP15 2Seven recommendations from Aarhus to COP15 3
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
... min) assay can detect H2O2 or peroxidase ... H2O2 oxidizes ADHP in a 1:1 stoichiometry ... at 530-571 nm, emission at 590-600 nm). ... a one-step, homogeneous, no wash assay system. ...
Biology Products: